Fig. 1.

Addition of a human B2m transgene does not affect the serum half-life of IgG in Tg32 mice

hB2M transgenic mice [25] were crossed onto FcRn-null and Tg32 mice. For FcRn-null (filled square), and FcRn-null expressing hB2M (filled triangle), and, Tg32/hB2M mice (filled diamond) 4 mice per group, and for Tg32 mice (filled circle) 3 mice per group were injected with 100 μg purified hIgG (GammaGard; Baxter Laboratories). Serial blood samples were collected at 1, 2, 3, 4, 7, 14, and 21 days after injection. Serum concentrations of hIgG were determined by ELISA analysis as previously described [22]. Results are presented as the percent of hIgG concentrations measured 24 h after IP injections. Addition of a human B2M transgene does not alter human FcRn dependent pharmacokinetics of hIgG.